Angel News
Angel News
Angel News

Back to Homepage

8th August 2018

Calculus Capital invests £2m in Oxford BioTherapeutics

Calculus Capital, the award-winning Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) specialist, has invested £2m in Oxford BioTherapeutics (OBT), a clinical-stage oncology company that is developing next-generation cancer treatments. OBT has a strong pipeline of ‘immune-oncology’ (IO) therapies that are intended to provide more targeted, specialised treatment strategies for patients by recruiting the body’s immune system to recognise and attack cancer cells. 

 

...

Register now to read full story

In order to read the full story we need you to register with us, please click the link below:

Register Now

Add a comment:

Name:

Email:

Comment:

Enter the characters in the image shown:



Back to Homepage